The Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil Ameliorates Insulin Resistance Induced by Chronic Angiotensin II Treatment in Rat Skeletal Muscle

Cardiorenal medicine

Guido Lastra ; Fernando R. Santos ; Payam Hooshmand ; Paria Hooshmand ; Irina Mugerfeld ; Annayya R. Aroor ; Vincent G. DeMarco ; James R. Sowers ; Erik J. Henriksen

关键词: Angiotensin II;    Glucose transport;    Red skeletal muscle;    Akt;    AS160;    AMPK;    p70 S6K1;   

DOI  :  10.1159/000353155

学科分类：心脏病和心血管学

来源: S Karger AG

【 摘 要 】

Abstract Angiotensin receptor (type 1) blockers (ARBs) can reduce both hypertension and insulin resistance induced by local and systemic activation of the renin-angiotensin-aldosterone system. The effectiveness of azilsartan medoxomil (AZIL-M), a novel imidazole-based ARB, to facilitate metabolic improvements in conditions of angiotensin II (Ang II)-associated insulin resistance is currently unknown. The aim of this study was to determine the impact of chronic AZIL-M treatment on glucose transpo.

【 授权许可】

CC BY